Immunophenotyping at the time of diagnosis distinguishes two groups of nasopharyngeal carcinoma patients: implications for adoptive immunotherapy.
Immunophenotyping at the time of diagnosis distinguishes two groups of nasopharyngeal carcinoma patients: implications for adoptive immunotherapy.
复制标题
诊断时的免疫表型区分了两组鼻咽癌患者：对过继性免疫治疗的影响。
DOI：
10.7150/ijbs.7.607
复制
发表时间：
2011
影响因子：
9.2
通讯作者：
Zeng YX
中科院分区：
文献类型：
--
作者：
Li J;Chen QY;Mo H;Zhang YL;Huang ZF;Zeng YX
背景资料：EB病毒特异性CTL（EBV-CTL）的连续免疫治疗已被用于治疗EB病毒相关的鼻咽癌（NPC），但只有一小部分患者表现出明显的临床反应。患者与方法：收集2005 ~ 2007年67例初治鼻咽癌患者和21例健康献血员。采用流式细胞仪分析（FACS）和51 Cr释放实验检测PBMCs和EBV-CTL的免疫学参数和免疫功能;采用免疫组化染色和统计学方法检测鼻咽癌细胞的分子特征。结果如下：根据接受任何治疗前外周血中CD 3 + T细胞的百分比，可将NPC患者分为两组（> 52.6%，来自健康对照的均值-2SE，NPC 1组; <52.6%，NPC 2组）。与第1组和健康对照组相比，第2组患者的CD 3 + CD 8 + T细胞、CD 3 + CD 4 + T细胞和CD 3 + CD 45 RO+记忆T细胞显著减少，而CD 3-CD 16 + NK细胞显著增加（P<0.001）。与NPC 1组相比，NPC 1组患者的EB病毒特异性T细胞反应较弱，其肿瘤细胞表达的EB病毒编码的潜伏膜蛋白（LMP）-1和HLA Ⅱ类蛋白水平较低（P<0.05）。结论：这些发现表明，可以根据NPC患者的免疫状态来区分NPC患者，这将影响EBV-CTL免疫治疗的效果。
Background: Adoptive immunotherapy with EBV-specific CTLs (EBV-CTL) has been used to treat EBV-associated nasopharyngeal carcinoma (NPC) but only a fraction of the patients shows noticeable clinical response. Patients and Methods: Sixty-seven newly diagnosed NPC patients from 2005 to 2007 and 21 healthy donors were collected. Immunological parameters and immune function of PBMCs and EBV-CTL were analyzed by flow cytometer analysis (FACS) and 51Cr releasing experiment; Molecular characteristics on NPC tumor cells were investigated by immunochemical staining and statistic analysis. Results: NPC patients can be classified into two groups based on the percentage of CD3+ T cells in peripheral blood before accepted any treatment, (>52.6%, mean-2SE from healthy controls, NPC Group 1; <52.6%, NPC Group 2). The patients in Group 2 showed a significant decrease of CD3+CD8+ T-cells, CD3+CD4+ T-cells and CD3+CD45RO+ memory T cells, and increase of CD3-CD16+ NK cells compared to Group 1 patients and healthy controls (P<0.001). EBV-specific T cell responses, were weaker in this group of patients and their tumor cells expressed lower levels of the EBV encoded latent membrane protein (LMP)-1 and HLA class II protein compared with the patients of NPC Group 1 (P<0.05) . Conclusion: These findings demonstrate that NPC patients could be distinguished on the basis of their immune status which will affect the efficacy of EBV-CTL immunotherapy.
登录
查看更多内容
影响因子：
2.8
作者：
Klaamas, K;Kurtenkov, O;Engstrand, L
通讯作者：
Engstrand, L
影响因子：
45.3
作者：
Comoli, P;Pedrazzoli, P;Siena, S
通讯作者：
Siena, S
影响因子：
3.7
作者：
Li J;Zeng XH;Mo HY;Rolén U;Gao YF;Zhang XS;Chen QY;Zhang L;Zeng MS;Li MZ;Huang WL;Wang XN;Zeng YX;Masucci MG
通讯作者：
Masucci MG
影响因子：
20.3
作者：
Bollard, Catherine M.;Gottschalk, Stephen;Heslop, Helen E.
通讯作者：
Heslop, Helen E.
影响因子：
2.7
作者：
Rooney, CM;Heslop, HE;Brenner, MK
通讯作者：
Brenner, MK